3.1
The appraisal committee considered evidence submitted by Novartis Pharmaceuticals and a review of this submission by the evidence review group. This appraisal was a Cancer Drugs Fund reconsideration of the NICE technology appraisal guidance on everolimus for the second-line treatment of advanced renal cell carcinoma. The company submission focused on cost-effectiveness analyses using a revised patient access scheme, which provides a simple discount to the list price of everolimus. The level of the discount is commercial in confidence.